CEL-SCI Corp (CVM)

Currency in USD
13.040
+1.740(+15.40%)
Closed·
8.110-4.930(-37.81%)
·
CVM Scorecard
Full Analysis
Quickly burning through cash
Unusual Post-Market activity
CVM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
11.59013.477
52 wk Range
1.98039.300
Key Statistics
Prev. Close
11.3
Open
11.9
Day's Range
11.59-13.477
52 wk Range
1.98-39.3
Volume
367.33K
Average Volume (3m)
803.66K
1-Year Change
-66.96%
Book Value / Share
1.37
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CVM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
300.030
Upside
+2,200.84%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory

CEL-SCI Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

CEL-SCI Corp Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company’s lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company’s LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Compare CVM to Peers and Sector

Metrics to compare
CVM
Peers
Sector
Relationship
P/E Ratio
−3.1x−3.1x−0.5x
PEG Ratio
−0.060.020.00
Price/Book
11.2x2.2x2.6x
Price / LTM Sales
-8.7x3.3x
Upside (Analyst Target)
-169.2%38.7%
Fair Value Upside
Unlock4.8%5.0%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 300.030
(+2,200.84% Upside)

Earnings

Latest Release
Aug 14, 2025
EPS / Forecast
-1.36 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

CVM Income Statement

People Also Watch

46.03
BMNR
-7.85%
18.08
SRPT
-0.99%
3.360
OPAD
-9.92%
28.84
CNC
+0.63%
71.36
MP
+2.19%

FAQ

What Stock Exchange Does CEL-SCI Trade On?

CEL-SCI is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for CEL-SCI?

The stock symbol for CEL-SCI is "CVM."

What Is the CEL-SCI Market Cap?

As of today, CEL-SCI market cap is 87.72M.

What Is CEL-SCI's Earnings Per Share (TTM)?

The CEL-SCI EPS (TTM) is -9.08.

From a Technical Analysis Perspective, Is CVM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has CEL-SCI Stock Split?

CEL-SCI has split 4 times.

How Many Employees Does CEL-SCI Have?

CEL-SCI has 44 employees.

What is the current trading status of CEL-SCI (CVM)?

As of 27 Aug 2025, CEL-SCI (CVM) is trading at a price of 13.04, with a previous close of 11.30. The stock has fluctuated within a day range of 11.59 to 13.48, while its 52-week range spans from 1.98 to 39.30.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.